← FDA DRUG APPROVALS

FDA NDA · NDA020945

NORVIR

Sponsor: ABBVIE

APPLICATION
NDA020945
TYPE
NDA
ORIGINAL APPROVAL
1999-06-29
LATEST ACTION
2020-10-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

NORVIR · ReferenceDiscontinued
RITONAVIR 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE · ORAL

Approval history

2020-10-21Labeling · Supplement 48 · standardLetterAP
2019-12-19Labeling · Supplement 47 · standardLetterAP
2019-08-21Labeling · Supplement 46 · standardLetterAP
2018-11-15Labeling · Supplement 45 · standardLabelAP
2017-06-29Labeling · Supplement 44 · standardLabelAP
2016-12-22Labeling · Supplement 42 · standardLabelAP
2016-11-22Labeling · Supplement 41 · standardLetterAP
2016-09-15Labeling · Supplement 43 · 901 requiredLabelAP
2015-11-10Labeling · Supplement 40 · standardLetterAP
2015-03-27Labeling · Supplement 39 · 901 requiredLabelAP
2015-03-16Labeling · Supplement 38 · standardLetterAP
2013-11-07Labeling · Supplement 36 · standardLabelAP
2012-11-19Labeling · Supplement 35 · standardLetterAP
2012-03-29Labeling · Supplement 33 · standardLetterAP
2012-02-17Labeling · Supplement 34 · 901 requiredLetterAP
2011-12-06Labeling · Supplement 32 · standardLabelAP
2010-04-27Labeling · Supplement 28 · 901 requiredLetterAP
2009-11-23Labeling · Supplement 26 · standardLetterAP
2008-10-01Labeling · Supplement 23 · standardLetterAP
2008-08-29Labeling · Supplement 22 · standardLabelAP
2008-05-16Labeling · Supplement 19 · standardLetterAP
2007-07-31Labeling · Supplement 20 · standardLetterAP
2007-05-10Labeling · Supplement 18 · standardLabelAP
2005-11-09Labeling · Supplement 16 · standardReviewAP
2005-10-06Efficacy · Supplement 17 · priorityReviewAP
2005-03-28Labeling · Supplement 14 · standardLabelAP
2003-09-10Labeling · Supplement 13 · standardLetterAP
2002-12-24Manufacturing (CMC) · Supplement 12 · standardAP
2002-09-30Manufacturing (CMC) · Supplement 11 · standardAP
2002-09-30Manufacturing (CMC) · Supplement 10 · standardAP
2002-09-17Manufacturing (CMC) · Supplement 9 · standardAP
2002-03-14Labeling · Supplement 8 · standardLetterAP
2001-08-21Labeling · Supplement 5 · standardLabelAP
2001-03-06Labeling · Supplement 7 · standardLetterAP
2001-02-05Manufacturing (CMC) · Supplement 6 · standardAP
2000-05-08Labeling · Supplement 4 · standardAP
1999-12-23Manufacturing (CMC) · Supplement 3 · standardAP
1999-10-26Labeling · Supplement 2 · standardAP
1999-10-21Labeling · Supplement 1 · standardAP
1999-06-29Type 3 - New Dosage Form · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →